Medicine:FinnProstate Group
From HandWiki
The FinnProstate Group (FP), or FinnProstate Study Group, is a group of scientific researchers in Finland who have conducted a series of clinical trials of treatments for prostate cancer.[1] The first publication by the group was in 1985[2] and the latest publication was in 2019.[3]
Clinical trials
The studies conducted by the FinnProstate group include the following:[1]
- FinnProstate-1 (FinnProstate-I; Finnish Multicentre Study of Prostatic Cancer) – ethinylestradiol 150 μg/day (1 mg/day initially) plus polyestradiol phosphate 80 mg/month (160 mg/month initially) versus orchiectomy for advanced prostate cancer[2][4][5]
- FinnProstate-2 (FinnProstate-II) – polyestradiol phosphate 160 mg/month (with or without low-dose aspirin) versus orchiectomy for advanced prostate cancer[6][7]
- FinnProstate-3 (FinnProstate-III) – cancelled
- FinnProstate-4 (FinnProstate-IV) – polyestradiol phosphate 160 mg/month versus buserelin (with cyproterone acetate 300 mg/day initially to prevent gonadotropin flare) in advanced or metastatic prostate cancer[8]
- FinnProstate-5 (FinnProstate-V) – cancelled
- FinnProstate-6 (FinnProstate-VI) – polyestradiol phosphate 240 month (320 mg/month initially) versus orchiectomy for advanced prostate cancer[9][10][11][12][13][14]
- FinnProstate-7 (FinnProstate-VII) – intermittent versus continuous androgen deprivation therapy for advanced prostate cancer[15][16][17]
- Other studies by the FinnProstate group[18][3]
Related trials
A related study, by the Finnish Zoladex Multicentre Study Group, assessed polyestradiol phosphate versus goserelin for advanced prostate cancer.[1][19] A British group also assessed polyestradiol phosphate 160 mg/month versus orchiectomy for advanced prostate cancer.[1][20] The SPCG-5 trial assessed polyestradiol phosphate 240 mg/month versus combined androgen blockade (triptorelin or orchiectomy plus flutamide) for advanced prostate cancer.[1][21][22][23]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Parenteral Oestrogens for Prostate Cancer: A Systematic Review of Clinical Effectiveness and Dose Response (CRD Report 33), York: Centre for Reviews and Dissemination/University of York/York Publishing Services, 2006, ISBN 1900640376, https://www.york.ac.uk/media/crd/crdreport33.pdf
- ↑ 2.0 2.1 "Early results of the Finnish Multicentre Study of Prostatic Cancer (Finnprostate)". Ann Chir Gynaecol 74 (6): 277–83. 1985. PMID 4096480.
- ↑ 3.0 3.1 "Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension". Eur Urol 76 (5): 586–595. November 2019. doi:10.1016/j.eururo.2019.07.001. PMID 31375279.
- ↑ "Comparison of primary orchiectomy and estrogen therapy in advanced prostatic cancer - a 2 years follow-up". Journal of Urology 135 (4): A339. April 1986. https://scholar.google.com/scholar?cluster=1823112295528156833.
- ↑ "Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study". Br J Urol 58 (5): 528–33. October 1986. doi:10.1111/j.1464-410x.1986.tb05461.x. PMID 3779355.
- ↑ "High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group". Br J Urol 63 (5): 512–4. May 1989. doi:10.1111/j.1464-410x.1989.tb05946.x. PMID 2659136.
- ↑ "Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group". Br J Urol 66 (1): 94–7. July 1990. doi:10.1111/j.1464-410x.1990.tb14872.x. PMID 2132303.
- ↑ "Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group". Ann Chir Gynaecol Suppl 206: 5–8. 1993. PMID 8291869.
- ↑ "Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group". Br J Urol 82 (1): 63–8. July 1998. doi:10.1046/j.1464-410x.1998.00688.x. PMID 9698663.
- ↑ "Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate". Scand J Urol Nephrol 39 (4): 294–300. 2005. doi:10.1080/00365590510031228. PMID 16261661.
- ↑ "Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy". Prostate 67 (4): 447–55. March 2007. doi:10.1002/pros.20547. PMID 17219379.
- ↑ "A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer". BJU Int 101 (9): 1090–5. May 2008. doi:10.1111/j.1464-410X.2007.07361.x. PMID 18070186.
- ↑ "Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors". Scand J Urol Nephrol 43 (4): 265–70. 2009. doi:10.1080/00365590902836500. PMID 19382005.
- ↑ "Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. FINNPROSTATE Group". Prostate 39 (3): 175–81. May 1999. doi:10.1002/(sici)1097-0045(19990515)39:3<175::aid-pros5>3.0.co;2-e. PMID 10334106.
- ↑ "The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer". J Urol 187 (6): 2074–81. June 2012. doi:10.1016/j.juro.2012.01.122. PMID 22498230.
- ↑ "Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects". Eur Urol 63 (1): 111–20. January 2013. doi:10.1016/j.eururo.2012.07.040. PMID 22857983.
- ↑ "Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII". Scand J Urol 48 (6): 513–22. December 2014. doi:10.3109/21681805.2014.901410. PMID 24679247.
- ↑ "Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population". Prostate 18 (2): 131–7. 1991. doi:10.1002/pros.2990180205. PMID 2006119.
- ↑ "Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study". Scand J Urol Nephrol 28 (2): 171–8. June 1994. doi:10.3109/00365599409180495. PMID 7939468.
- ↑ "Oestrogen dosage in prostatic cancer: the threshold effect?". Br J Urol 64 (3): 290–6. September 1989. doi:10.1111/j.1464-410x.1989.tb06016.x. PMID 2679960.
- ↑ "Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study". Urology 55 (3): 328–33. March 2000. doi:10.1016/s0090-4295(99)00580-4. PMID 10699602.
- ↑ "Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5". Scand J Urol Nephrol 36 (6): 405–13. 2002. doi:10.1080/003655902762467549. PMID 12623503.
- ↑ "Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5". Scand J Urol Nephrol 42 (3): 220–9. 2008. doi:10.1080/00365590801943274. PMID 18432528.
 |  |
